A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”
Study finds varying cardiovascular risks associated with different hormonal contraceptives
Certain hormonal contraceptives are associated with a higher stroke and heart attack risk, finds a large study from Denmark in The BMJ today that draws